# US 2025/0145958 A1 · Generating Vasculogenic Cell Populations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145958 A1
- Document ID: US20250145958A1
- Status: Published application
- Kind: A1
- Application number: 18/819,158
- Filed: 2024-08-29
- Published: 2025-05-08
- Earliest claimed: 2013-06-12
- Assignees: Wisconsin Alumni Research Foundation
- Applicants: Wisconsin Alumni Research Foundation
- Inventors: Igor Slukvin; Akhilesh Kumar
- Web page: https://patentgrep.com/patent/US20250145958A1

## CPC

- C12N 5/0661: {Smooth muscle cells}
- A61K 35/34: Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)
- A61K 35/44: Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- C12N 2500/90: Serum-free medium, which may still contain naturally-sourced components
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/135: Platelet-derived growth factor [PDGF]
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/165: Vascular endothelial growth factor [VEGF]
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2506/02: from embryonic cells
- C12N 2506/1346: from mesenchymal stem cells
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates generally to methods and compositions useful for therapeutic vascular tissue engineering. In particular, the present invention provides methods for generating substantially pure populations of vasculogenic cells from human mesenchymal progenitor, and methods and compositions for clinical applications in the field of regenerative medicine.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A method for obtaining an expanded isolated population of primate vasculogenic cells for vascular tissue engineering and for pharmaceutical use, the method comprising:
obtaining mesenchymal stem cells from a mesenchymoangioblasts (MAB)-derived colony of mesenchymal progenitors,
expanding the population of mesenchymal stem cells in vitro, and
contacting the expanded MSC population to a culture medium comprising an effective amount of sphingosylphosphorylcholine (SPC) and an effective amount of Transforming Growth Factor beta (TGFβ) to promote differentiation of the contacts MSC population into vasculogenic cells, wherein the vasculogenic cells are smooth muscle cells.

### Claim 24

A method for obtaining an expanded isolated population of primate vasculogenic cells for vascular tissue engineering and for pharmaceutical use, the method comprising:
obtaining mesenchymal stem cells from a mesenchymoangioblasts (MAB)-derived colony of mesenchymal progenitors,
expanding the population of mesenchymal stem cells in vitro,
culturing a mesenchymal stem cell colony in a culture medium with FVF2 to obtain mesenchymal stem cell lines, and
contacting the expanded MSC population to a culture medium comprising an effective amount of sphingosylphosphorylcholine (SPC) and an effective amount of Transforming Growth Factor beta (TGFβ) to promote differentiation of the contacts MSC population into vasculogenic cells, wherein the vasculogenic cells are smooth muscle cells.

### Claim 25 (depends on 23, 24)

The method according to claim 23 or 24, wherein the vasculogic cells are smooth muscle cells that express at least one molecular marker of smooth muscle cells selected from α-SMA (a-smooth muscle actin), calponin, desmin, SM22 (Smooth muscle protein of 22 kDa), MYOCD (myocardin), and MYH11 (Myosin Heavy Chain 11).

### Claim 26 (depends on 25)

The method of claim 25, wherein the vasculogenic cells are smooth muscle cells that express at least two molecular markers of smooth muscle cells.

### Claim 27 (depends on 23, 24)

The method according to claim 23 or 24, wherein the colony of mesenchymal progenitors is a colony of PDGFRβ+ (Platelet Derived Growth Factor Receptor β)/IEMCNhigh/CD105low; 65CD248−/CD73−/CD31−primate mesenchymal progenitors.

### Claim 28 (depends on 23, 24)

The method according to claim 23 or 24, wherein the primate is human.

### Claim 29 (depends on 23, 24)

The method according to claim 23 or 24, wherein the colony of mesenchymal progenitors is clonal.

### Claim 30 (depends on 23, 24)

The method according to claim 23 or 24, wherein the colony of mesenchymal progenitors is polyclonal.
